MX2023009623A - Anticuerpos anti-vista y usos de estos. - Google Patents
Anticuerpos anti-vista y usos de estos.Info
- Publication number
- MX2023009623A MX2023009623A MX2023009623A MX2023009623A MX2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- vista
- vista antibodies
- domain
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150995P | 2021-02-18 | 2021-02-18 | |
| PCT/US2022/016912 WO2022178203A1 (en) | 2021-02-18 | 2022-02-18 | Anti-vista antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009623A true MX2023009623A (es) | 2023-10-23 |
Family
ID=82931719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009623A MX2023009623A (es) | 2021-02-18 | 2022-02-18 | Anticuerpos anti-vista y usos de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240132593A1 (enExample) |
| EP (1) | EP4294530A4 (enExample) |
| JP (1) | JP2024508764A (enExample) |
| KR (1) | KR20230157970A (enExample) |
| CN (1) | CN117177995A (enExample) |
| AU (1) | AU2022223973A1 (enExample) |
| BR (1) | BR112023016533A2 (enExample) |
| CA (1) | CA3208872A1 (enExample) |
| IL (1) | IL305310A (enExample) |
| MX (1) | MX2023009623A (enExample) |
| WO (1) | WO2022178203A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| PE20250933A1 (es) * | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| PE20210687A1 (es) * | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
| WO2020140094A1 (en) * | 2018-12-27 | 2020-07-02 | Gigagen, Inc. | Anti-b7-h3 binding proteins and methods of use thereof |
-
2022
- 2022-02-18 US US18/276,417 patent/US20240132593A1/en active Pending
- 2022-02-18 BR BR112023016533A patent/BR112023016533A2/pt unknown
- 2022-02-18 JP JP2023549992A patent/JP2024508764A/ja active Pending
- 2022-02-18 MX MX2023009623A patent/MX2023009623A/es unknown
- 2022-02-18 EP EP22756977.9A patent/EP4294530A4/en active Pending
- 2022-02-18 AU AU2022223973A patent/AU2022223973A1/en active Pending
- 2022-02-18 WO PCT/US2022/016912 patent/WO2022178203A1/en not_active Ceased
- 2022-02-18 CA CA3208872A patent/CA3208872A1/en active Pending
- 2022-02-18 IL IL305310A patent/IL305310A/en unknown
- 2022-02-18 KR KR1020237031291A patent/KR20230157970A/ko active Pending
- 2022-02-18 CN CN202280027463.XA patent/CN117177995A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4294530A4 (en) | 2025-07-16 |
| JP2024508764A (ja) | 2024-02-28 |
| US20240132593A1 (en) | 2024-04-25 |
| KR20230157970A (ko) | 2023-11-17 |
| BR112023016533A2 (pt) | 2023-11-21 |
| CA3208872A1 (en) | 2022-08-25 |
| WO2022178203A1 (en) | 2022-08-25 |
| EP4294530A1 (en) | 2023-12-27 |
| CN117177995A (zh) | 2023-12-05 |
| AU2022223973A1 (en) | 2023-09-07 |
| IL305310A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024003715A1 (es) | Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso. | |
| JOP20230312A1 (ar) | أجسام مضادة لـ ccr8 واستخداماتها | |
| CL2022001769A1 (es) | Anticuerpos anti-cd73 y usos de estos. | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| MX2020012588A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos. | |
| CO2022003582A2 (es) | Métodos para el tratamiento de la oftalmopatía tiroidea | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| EA201592074A1 (ru) | Композиции и способы изменения сигнальной системы вторичного мессенджера | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| EA201890247A1 (ru) | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин | |
| MX2024003107A (es) | Agonistas de ahr. | |
| SA523451582B1 (ar) | Ccr8 الأجسام المضادة لـ | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| EA201892500A1 (ru) | Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции | |
| EA202193296A1 (ru) | Конструкции для rnai, предназначенные для подавления экспрессии scap, и способы их применения | |
| MX2023012672A (es) | Nuevo anticuerpo anti-vista estable. | |
| PE20230460A1 (es) | Anticuerpos anti-cd200r1 y metodos de uso de estos | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| MX2020013923A (es) | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. | |
| WO2020242719A3 (en) | Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения |